TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

• Autors principals: Harbani K. Malik-Chaudhry (Autor), Kirthana Prabhakar (Autor), Harshad S. Ugamraj (Autor), Andrew A. Boudreau (Autor), Benjamin Buelow (Autor), Kevin Dang (Autor), Laura M. Davison (Autor), Katherine E. Harris (Autor), Brett Jorgensen (Autor), Heather Ogana (Autor), Duy Pham (Autor), Ute Schellenberger (Autor), Wim Van Schooten (Autor), Roland Buelow (Autor), Suhasini Iyer (Autor), Nathan D. Trinklein (Autor), Udaya S. Rangaswamy (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager b...